European Immunoassay Market

Immunoassay accounted for 26% share of the IVD market in 2013. The recent technological development focuses more on detecting one or several proteins in a patient’s blood or serum. The growth of the immunoassays market will primarily be dependent on the development of novel assays in prime areas, such as cardiology, oncology, and various autoimmune diseases, as these novel assays will help companies gain a competitive edge.

The rising automation trend is a major driver for the growth of immunoassay market as it helps reduce the cost of labor, which accounts for around 50% of the total cost of a test. There has been an increase in the awareness of health and fitness across the globe and hence, most people are now undergoing routine tests regularly.

The Centers for Medicare & Medicaid Services (CMS) has estimated that healthcare spending in the U.S. is expected to grow from $2.7 trillion in 2011 to about $4.6 trillion in 2018, at a CAGR of 6.8%, for the given period. Similarly, in emerging countries, awareness and an increasing middle-class population, with a more disposable income to spend on healthcare, will be a driving force for the growth of this market.

The report ‘European Immunoassay Market forecast for 2018’ analyzes the market by segments such as reagents and end instruments.

Europe holds second-largest market position in the global immunoassay market. Germany commanded the largest share 20% at $790.6 million in 2013, and is expected to reach $1066.7 million by 2018, at a CAGR of 6.5%, from 2013 to 2018.

The report also provides an extensive competitive landscaping of companies operating in immunoassay market. The major players immunoassay market are Siemens (Germany), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Ortho Clinical Diagnostics (U.S.), and bioMerieux SA (France).

Segment and country-specific company shares, news & deals, mergers and acquisitions, segment specific pipeline products, product approvals and product recalls of the major companies have been detailed in this report.

Customization Options

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:

Opportunity Analysis

• Unmet needs, revenue pockets, and potential areas for expansion for immunoassay market
• Comprehensive review of key component providers, analyzers, and test kit providers

Current and Emerging Products

• Analysis of current and emerging immunoassay and immunodiagnostic tests
• Review of current instrumentation technologies

Pricing Trends

• Pricing trend of immunoassay tests

Product Analysis

• Usage pattern (in-depth trend analysis) of products (segment wise)
• Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment level
• End-user adoption rate analysis of the products (segment wise and country wise)
• Comprehensive coverage of product approvals, pipeline products, and product recalls

Brand/Product Perception Matrix

• Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virility and tonality of blogs
• Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

Alternative Products: Impact analysis

MMM’s healthcare decision making quadrant is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like patient dynamics (patient pool, epidemiology of disease, preference towards surgeries/alternative therapies) and macroeconomic indicators (number of hospitals and orthopedic clinics, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure).

1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)

2 Executive Summary
 

3 Market Overview
 

4 Immunoassay-Europe, by Applications
4.1 Split by Geography
4.1 Immunoassay-Spain by Applications
4.1 Immunoassay-United Kingdom by Applications
4.1 Immunoassay-France by Applications
4.1 Immunoassay-Germany by Applications
4.1 Immunoassay-Italy by Applications
4.1 Immunoassay-Rest of Europe by Applications
4.2 Immunoassay-Europe-Infectious disease
4.2.1 Immunoassay-Europe-Infectious disease, by Geographies
4.2.1.1 Immunoassay-Spain-Infectious disease
4.2.1.2 Immunoassay-United Kingdom-Infectious disease
4.2.1.3 Immunoassay-France-Infectious disease
4.2.1.4 Immunoassay-Germany-Infectious disease
4.2.1.5 Immunoassay-Italy-Infectious disease
4.2.1.6 Immunoassay-Rest of Europe-Infectious disease
4.3 Immunoassay-Europe-Endocrine disorders
4.3.1 Immunoassay-Europe-Endocrine disorders, by Geographies
4.3.1.1 Immunoassay-Spain-Endocrine disorders
4.3.1.2 Immunoassay-United Kingdom-Endocrine disorders
4.3.1.3 Immunoassay-France-Endocrine disorders
4.3.1.4 Immunoassay-Germany-Endocrine disorders
4.3.1.5 Immunoassay-Italy-Endocrine disorders
4.3.1.6 Immunoassay-Rest of Europe-Endocrine disorders
4.4 Immunoassay-Europe-Bone and Mineral Disorders
4.4.1 Immunoassay-Europe-Bone and Mineral Disorders, by Geographies
4.4.1.1 Immunoassay-Spain-Bone and Mineral Disorders
4.4.1.2 Immunoassay-United Kingdom-Bone and Mineral Disorders
4.4.1.3 Immunoassay-France-Bone and Mineral Disorders
4.4.1.4 Immunoassay-Germany-Bone and Mineral Disorders
4.4.1.5 Immunoassay-Italy-Bone and Mineral Disorders
4.4.1.6 Immunoassay-Rest of Europe-Bone and Mineral Disorders
4.5 Immunoassay-Europe-Cancer
4.5.1 Immunoassay-Europe-Cancer, by Geographies
4.5.1.1 Immunoassay-Spain-Cancer
4.5.1.2 Immunoassay-United Kingdom-Cancer
4.5.1.3 Immunoassay-France-Cancer
4.5.1.4 Immunoassay-Germany-Cancer
4.5.1.5 Immunoassay-Italy-Cancer
4.5.1.6 Immunoassay-Rest of Europe-Cancer
4.6 Immunoassay-Europe-Cardiovascular Disorders
4.6.1 Immunoassay-Europe-Cardiovascular Disorders, by Geographies
4.6.1.1 Immunoassay-Spain-Cardiovascular Disorders
4.6.1.2 Immunoassay-United Kingdom-Cardiovascular Disorders
4.6.1.3 Immunoassay-France-Cardiovascular Disorders
4.6.1.4 Immunoassay-Germany-Cardiovascular Disorders
4.6.1.5 Immunoassay-Italy-Cardiovascular Disorders
4.6.1.6 Immunoassay-Rest of Europe-Cardiovascular Disorders
4.7 Immunoassay-Europe-Blood Disorders
4.7.1 Immunoassay-Europe-Blood Disorders , by Geographies
4.7.1.1 Immunoassay-Spain-Blood Disorders
4.7.1.2 Immunoassay-United Kingdom-Blood Disorders
4.7.1.3 Immunoassay-France-Blood Disorders
4.7.1.4 Immunoassay-Germany-Blood Disorders
4.7.1.5 Immunoassay-Italy-Blood Disorders
4.7.1.6 Immunoassay-Rest of Europe-Blood Disorders
4.8 Immunoassay-Europe-Auto-immune Diseases
4.8.1 Immunoassay-Europe-Auto-immune Diseases, by Geographies
4.8.1.1 Immunoassay-Spain-Auto-immune Diseases
4.8.1.2 Immunoassay-United Kingdom-Auto-immune Diseases
4.8.1.3 Immunoassay-France-Auto-immune Diseases
4.8.1.4 Immunoassay-Germany-Auto-immune Diseases
4.8.1.5 Immunoassay-Italy-Auto-immune Diseases
4.8.1.6 Immunoassay-Rest of Europe-Auto-immune Diseases
4.9 Immunoassay-Europe-Toxicology
4.9.1 Immunoassay-Europe-Toxicology, by Geographies
4.9.1.1 Immunoassay-Spain-Toxicology
4.9.1.2 Immunoassay-United Kingdom-Toxicology
4.9.1.3 Immunoassay-France-Toxicology
4.9.1.4 Immunoassay-Germany-Toxicology
4.9.1.5 Immunoassay-Italy-Toxicology
4.9.1.6 Immunoassay-Rest of Europe-Toxicology
 

5 Immunoassay-Europe, by Types
5.1 Split by Geography
5.2 Immunoassay-Spain by Types
5.1 Immunoassay-United Kingdom by Types
5.1 Immunoassay-France by Types
5.1 Immunoassay-Germany by Types
5.1 Immunoassay-Italy by Types
5.1 Immunoassay-Rest of Europe by Types
5.2 Immunoassay - Europe - Medium Throughput
5.3 Immunoassay - Europe - Medium Throughput
5.4 Immunoassay - Europe - Low Throughput
5.5 Immunoassay - Europe - Low Throughput
5.6 Immunoassay - Europe - High Throughput
5.7 Immunoassay - Europe - High Throughput
 

6 Immunoassay-Europe, by Technologies
6.1 Split by Geography
6.3 Immunoassay-Spain by Technologies
6.1 Immunoassay-United Kingdom by Technologies
6.1 Immunoassay-France by Technologies
6.1 Immunoassay-Germany by Technologies
6.1 Immunoassay-Italy by Technologies
6.1 Immunoassay-Rest of Europe by Technologies
6.2 Fluorescence Immunoassays (FIA)-Europe
6.2.1 Fluorescence Immunoassays (FIA)-Europe, by Geographies
6.2.1.1 Fluorescence Immunoassays (FIA)-Spain
6.2.1.2 Fluorescence Immunoassays (FIA)-United Kingdom
6.2.1.3 Fluorescence Immunoassays (FIA)-France
6.2.1.4 Fluorescence Immunoassays (FIA)-Germany
6.2.1.5 Fluorescence Immunoassays (FIA)-Italy
6.2.1.6 Fluorescence Immunoassays (FIA)-Rest of Europe
6.3 Chemiluminescence Immunoassays (CLIA)-Europe
6.3.1 Chemiluminescence Immunoassays (CLIA)-Europe, by Geographies
6.3.1.1 Chemiluminescence Immunoassays (CLIA)-Spain
6.3.1.2 Chemiluminescence Immunoassays (CLIA)-United Kingdom
6.3.1.3 Chemiluminescence Immunoassays (CLIA)-France
6.3.1.4 Chemiluminescence Immunoassays (CLIA)-Germany
6.3.1.5 Chemiluminescence Immunoassays (CLIA)-Italy
6.3.1.6 Chemiluminescence Immunoassays (CLIA)-Rest of Europe
6.4 Radioimmunoassays (RIA)-Europe
6.4.1 Radioimmunoassays (RIA)-Europe, by Geographies
6.4.1.1 Radioimmunoassays (RIA)-Spain
6.4.1.2 Radioimmunoassays (RIA)-United Kingdom
6.4.1.3 Radioimmunoassays (RIA)-France
6.4.1.4 Radioimmunoassays (RIA)-Germany
6.4.1.5 Radioimmunoassays (RIA)-Italy
6.4.1.6 Radioimmunoassays (RIA)-Rest of Europe
6.5 Enzyme Immunoassays (EIA)-Europe
6.5.1 Enzyme Immunoassays (EIA)-Europe, by Geographies
6.5.1.1 Enzyme Immunoassays (EIA)-Spain
6.5.1.2 Enzyme Immunoassays (EIA)-United Kingdom
6.5.1.3 Enzyme Immunoassays (EIA)-France
6.5.1.4 Enzyme Immunoassays (EIA)-Germany
6.5.1.5 Enzyme Immunoassays (EIA)-Italy
6.5.1.6 Enzyme Immunoassays (EIA)-Rest of Europe
 

7 Immunoassay-Europe, by Geographies
7.1 Immunoassay-Spain
7.1.1 Immunoassay-Spain, by Applications
7.1.1.1 Immunoassay-Spain-Infectious disease
7.1.1.2 Immunoassay-Spain-Endocrine disorders
7.1.1.3 Immunoassay-Spain-Bone and Mineral Disorders
7.1.1.4 Immunoassay-Spain-Cancer
7.1.1.5 Immunoassay-Spain-Cardiovascular Disorders
7.1.1.6 Immunoassay-Spain-Blood Disorders
7.1.1.7 Immunoassay-Spain-Auto-immune Diseases
7.1.1.8 Immunoassay-Spain-Toxicology
7.1.2 Immunoassay-Spain, by Technologies
7.1.2.1 Fluorescence Immunoassays (FIA)-Spain
7.1.2.2 Chemiluminescence Immunoassays (CLIA)-Spain
7.1.2.3 Radioimmunoassays (RIA)-Spain
7.1.2.4 Enzyme Immunoassays (EIA)-Spain
7.2 Immunoassay-United Kingdom
7.2.1 Immunoassay-United Kingdom, by Applications
7.2.1.1 Immunoassay-United Kingdom-Infectious disease
7.2.1.2 Immunoassay-United Kingdom-Endocrine disorders
7.2.1.3 Immunoassay-United Kingdom-Bone and Mineral Disorders
7.2.1.4 Immunoassay-United Kingdom-Cancer
7.2.1.5 Immunoassay-United Kingdom-Cardiovascular Disorders
7.2.1.6 Immunoassay-United Kingdom-Blood Disorders
7.2.1.7 Immunoassay-United Kingdom-Auto-immune Diseases
7.2.1.8 Immunoassay-United Kingdom-Toxicology
7.2.2 Immunoassay-United Kingdom, by Technologies
7.2.2.1 Fluorescence Immunoassays (FIA)-United Kingdom
7.2.2.2 Chemiluminescence Immunoassays (CLIA)-United Kingdom
7.2.2.3 Radioimmunoassays (RIA)-United Kingdom
7.2.2.4 Enzyme Immunoassays (EIA)-United Kingdom
7.3 Immunoassay-France
7.3.1 Immunoassay-France, by Applications
7.3.1.1 Immunoassay-France-Infectious disease
7.3.1.2 Immunoassay-France-Endocrine disorders
7.3.1.3 Immunoassay-France-Bone and Mineral Disorders
7.3.1.4 Immunoassay-France-Cancer
7.3.1.5 Immunoassay-France-Cardiovascular Disorders
7.3.1.6 Immunoassay-France-Blood Disorders
7.3.1.7 Immunoassay-France-Auto-immune Diseases
7.3.1.8 Immunoassay-France-Toxicology
7.3.2 Immunoassay-France, by Technologies
7.3.2.1 Fluorescence Immunoassays (FIA)-France
7.3.2.2 Chemiluminescence Immunoassays (CLIA)-France
7.3.2.3 Radioimmunoassays (RIA)-France
7.3.2.4 Enzyme Immunoassays (EIA)-France
7.4 Immunoassay-Germany
7.4.1 Immunoassay-Germany, by Applications
7.4.1.1 Immunoassay-Germany-Infectious disease
7.4.1.2 Immunoassay-Germany-Endocrine disorders
7.4.1.3 Immunoassay-Germany-Bone and Mineral Disorders
7.4.1.4 Immunoassay-Germany-Cancer
7.4.1.5 Immunoassay-Germany-Cardiovascular Disorders
7.4.1.6 Immunoassay-Germany-Blood Disorders
7.4.1.7 Immunoassay-Germany-Auto-immune Diseases
7.4.1.8 Immunoassay-Germany-Toxicology
7.4.2 Immunoassay-Germany, by Technologies
7.4.2.1 Fluorescence Immunoassays (FIA)-Germany
7.4.2.2 Chemiluminescence Immunoassays (CLIA)-Germany
7.4.2.3 Radioimmunoassays (RIA)-Germany
7.4.2.4 Enzyme Immunoassays (EIA)-Germany
7.5 Immunoassay-Italy
7.5.1 Immunoassay-Italy, by Applications
7.5.1.1 Immunoassay-Italy-Infectious disease
7.5.1.2 Immunoassay-Italy-Endocrine disorders
7.5.1.3 Immunoassay-Italy-Bone and Mineral Disorders
7.5.1.4 Immunoassay-Italy-Cancer
7.5.1.5 Immunoassay-Italy-Cardiovascular Disorders
7.5.1.6 Immunoassay-Italy-Blood Disorders
7.5.1.7 Immunoassay-Italy-Auto-immune Diseases
7.5.1.8 Immunoassay-Italy-Toxicology
7.5.2 Immunoassay-Italy, by Technologies
7.5.2.1 Fluorescence Immunoassays (FIA)-Italy
7.5.2.2 Chemiluminescence Immunoassays (CLIA)-Italy
7.5.2.3 Radioimmunoassays (RIA)-Italy
7.5.2.4 Enzyme Immunoassays (EIA)-Italy
7.6 Immunoassay-Rest of Europe
7.6.1 Immunoassay-Rest of Europe, by Applications
7.6.1.1 Immunoassay-Rest of Europe-Infectious disease
7.6.1.2 Immunoassay-Rest of Europe-Endocrine disorders
7.6.1.3 Immunoassay-Rest of Europe-Bone and Mineral Disorders
7.6.1.4 Immunoassay-Rest of Europe-Cancer
7.6.1.5 Immunoassay-Rest of Europe-Cardiovascular Disorders
7.6.1.6 Immunoassay-Rest of Europe-Blood Disorders
7.6.1.7 Immunoassay-Rest of Europe-Auto-immune Diseases
7.6.1.8 Immunoassay-Rest of Europe-Toxicology
7.6.2 Immunoassay-Rest of Europe, by Technologies
7.6.2.1 Fluorescence Immunoassays (FIA)-Rest of Europe
7.6.2.2 Chemiluminescence Immunoassays (CLIA)-Rest of Europe
7.6.2.3 Radioimmunoassays (RIA)-Rest of Europe
7.6.2.4 Enzyme Immunoassays (EIA)-Rest of Europe

Please fill in the form below to receive a free copy of the Summary of this Report

* First Name :

* Last Name :

* Designation :

* Company :

* Email(Username) :

* Phone :

* Country :

-- Select Country -- India Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antigua Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia Herzegovina Botswana Brazil British Virgin Island Brunei Darussalam Bulgaria Burkina Faso Burundi Cote d'Ivoire Cambodia Cameroon Canada Cape Verde Cayman Isls Central African Republic Chad Chile China Colombia Comoros Congo Cook Island Costa Rica Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Falkland Islands (Malvinas) Fiji Finl France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenl Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Holy See Honduras Hong Kong Special Administrative Hungary Iceland Indonesia Iran (Islamic Republic of Iran) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Special Administrative Region of China Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Micronesia Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherland Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Islands Northern Mariana Islands Norway Occupied Palestinian Territory Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Republic of Korea Republic of Moldova Romania Russian Federation Rwa Saint Helena Saint Kitts Nevis Saint Lucia Saint Pierre Miquelon Saint Vincent the Grenadines Samoa San Marino Sao Tome Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Svalbard Jan Mayen Islands Swazil Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Thailand The former Yugoslav Republic of Macedonia Timor-Leste Togo Tokelau Tonga Trinidad Tobago Tunisia Turkey Turkmenistan Turks Caicos Isls Tuvalu Uga Ukraine United Arab Emirates United Kingdom United Republic of Tanzania United States United States Virgin Isls Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Wallis Futuna Isls Western Sahara Yemen Yugoslavia Zambia Zimbabwe

Comments :

Reports Interested in :European Immunoassay Market

* Enter the text from the image to the text box :